Daniel Chung, DO, MA
Chief Medical Officer, SparingVision

Daniel Chung, DO, MA

Dr. Chung is the Chief Medical Officer of SparingVision where he spearheads the clinical development of new therapies and leads medical affairs, educational, and patient advocacy efforts. He has extensive experience in medical strategy and gene therapy, previously serving as the Ophthalmology Lead at Spark Therapeutics, where he played a pivotal role in the approval of Luxturna™ for RPE65-associated inherited retinal generation, the first gene therapy to be approved in the US for a genetic disease.

Prior to Spark, Dr. Chung worked for 11 years at the Scheie Eye Institute within the Perelman School of Medicine at the University of Pennsylvania, specializing in pre-clinical and translational research of gene-based therapies for inherited retinal diseases.

Dr. Chung received his medical degree from the New York College of Osteopathic Medicine in 1994 and completed postgraduate training at the National Eye Institute, Summa Health Systems and Cole Eye Institute at the Cleveland Clinic Foundation.